Plexāā Advances U.S. Expansion with BLOOM⁴³ Debut at Plastic Surgery The Meeting 2025
October 2025 – New Orleans, LA – Plexāā, the UK MedTech company revolutionizing the underserved preoperative space by combining prehabilitation and preconditioning with the power of supraphysiological preconditioning™, advanced its U.S. growth strategy at Plastic Surgery The Meeting 2025 in New Orleans. The company used the global gathering of leading reconstructive and aesthetic surgeons to introduce BLOOM⁴³ to the U.S. market and initiate high-impact collaborations with healthcare providers.
At its stand, Plexāā introduced BLOOM⁴³ to clinical leaders from hospitals, surgical practices, and health systems, opening discussions for pilot integrations and long-term adoption. Conversations focused on embedding BLOOM⁴³ into perioperative care pathways to reduce wound-healing complications and improve patients experience. Engagements with several leading U.S. institutions are now progressing toward implementation programmes and formal collaboration.
Our goal is to make Prehab™ the standard of care for all surgeries through preconditioning and prehabilitation,” said Dr Saahil Mehta, Plastic Surgeon, CEO and Founder of Plexāā. “The response from U.S. providers confirmed that BLOOM⁴³ is addressing a real need in surgical preparation and patient care. These discussions mark a defining moment in our U.S. journey.”
The Plexāā team connected with clinical decision-makers from both U.S. and international organisations, with many expressing interest in implementation across their organizations and collaborative research. The company will now build on these engagements as it refines its market entry and scale-up strategy.
Alongside its clinical launch activity, Plexāā proudly sponsored Project Regenerate’s An Evening of Art and Conversations, an exhibition held in New Orleans during the conference. The immersive experience explores the emotional journey of navigating breast cancer through a fusion of photography and generative AI. Drawing from the lived experiences of women who have faced breast cancer, the work reveals the often unseen mental landscape of diagnosis, treatment, and recovery — a mission deeply aligned with Plexāā’s commitment to compassionate surgical care.
“Being part of a project that brings visibility to the psychological and physical impact of breast cancer felt very personal and important,” said Gaele Lalahy, Chief Operating Officer of Plexāā. “Innovation in surgery is not just about devices — it is about the patient experience that surrounds them.”
More about the exhibition can be found at www.projectregenerate.com.
With implementation discussions and strategic collaborations underway, Plexāā is entering its next phase of U.S. growth. The company remains committed to making Prehab™ the global standard of care — ensuring every patient enters surgery stronger, more confident, and better prepared.
About Plexāā
Plexāā is a pioneering medtech company focused on improving surgical outcomes through devices and digital products. Its flagship device, BLOOM⁴³, enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect up to one in three women undergoing breast surgery.
Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes. Please visit the company website and follow the company on Instagram and LinkedIn.
Media Contact:
marketing@plexaa.com